| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 01/07/2014 | CA2563117C Treatment of type 1 diabetes with inhibitors of macrophage migration inhibitory factor |
| 01/07/2014 | CA2464472C Antibody targeting compounds |
| 01/07/2014 | CA2453967C Peptides effective in the treatment of tumors and other conditions requiring the removal or destruction of cells |
| 01/07/2014 | CA2336875C Multivalent human-bovine rotavirus vaccine |
| 01/07/2014 | CA2319404C Recombinant lipidated psaa protein, methods of preparation and use |
| 01/07/2014 | CA2318405C Antibodies to death receptor 4(dr4) and uses thereof |
| 01/07/2014 | CA2286798C Alpha-o-linked glycoconjugates with clustered(2,6)-st epitopes, methods of preparation and uses thereof |
| 01/03/2014 | WO2014005153A2 Methods for treating mds1-evi1 mediated cancer |
| 01/03/2014 | WO2014005072A1 Methods and compositions for natural killer cells |
| 01/03/2014 | WO2014004866A1 Combinations of modalities for the treatment of diabetes |
| 01/03/2014 | WO2014004436A2 Crystalline anti-human il-23 antibodies |
| 01/03/2014 | WO2014004385A2 Anti-cancer vaccines |
| 01/03/2014 | WO2014004361A1 Attenuated streptococcus suis vaccines and methods of making and use thereof |
| 01/03/2014 | WO2014003821A1 Methods and compositions for segregating target nucleic acid from mixed nucleic acid samples |
| 01/03/2014 | WO2014003744A1 Anti-cxcl9, anti-cxcl 10, anti-cxcl 11, anti-cxcl 13, anti-cxcr3 and anti-cxcr5 agents for inflammatory disorder |
| 01/03/2014 | WO2014003742A1 Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation |
| 01/03/2014 | WO2014003531A1 Nasal vaccine against the development of atherosclerosis disease and fatty liver |
| 01/03/2014 | WO2014003142A1 Antibody |
| 01/03/2014 | WO2014003008A1 Novel histamine liberator contained in human sweat |
| 01/03/2014 | WO2014002035A2 A human monoclonal antibody against the vp1 protein of jc virus |
| 01/03/2014 | WO2014001820A1 Japanese cedar peptide for preventing or treating allergy |
| 01/03/2014 | WO2014001572A1 Composition for use in mycobacteria therapy |
| 01/03/2014 | WO2014001570A1 Composition for use in mycobacteria vaccination |
| 01/03/2014 | WO2014001482A1 Treating diseases by modulating a specific isoform of mkl1 |
| 01/03/2014 | WO2014001326A1 Method for the selection and production of tailor-made, selective and multi-specific therapeutic molecules comprising at least two different targeting entities and uses thereof |
| 01/03/2014 | WO2014001183A1 Pharmaceutical composition having synergistic action of direct catalase inhibitors and modulators of no metabolism or of extracellular superoxide anion production which lead to catalase destruction |
| 01/03/2014 | WO2014000338A1 Application of composite of anti-cd146 antibody and anti-vegf antibody in preparing medicine for suppressing tumor |
| 01/03/2014 | WO2014000058A1 Method of treating glucose metabolism disorders |
| 01/03/2014 | WO2014000042A1 COMPOSITIONS AND METHODS FOR MODIFYING TGF-β FAMILY LIGANDS |
| 01/03/2014 | WO2014000027A1 Prevention and treatment of haematological conditions |
| 01/03/2014 | WO2014000026A1 Recombinant viral vectors and uses therefor |
| 01/03/2014 | WO2013151662A9 Therapies, vaccines, and predictive methods for infectious salmon anemia virus |
| 01/03/2014 | CA2877906A1 Combinations of modalities for the treatment of diabetes |
| 01/03/2014 | CA2877817A1 Attenuated streptococcus suis vaccines and methods of making and use thereof |
| 01/03/2014 | CA2877598A1 A human monoclonal antibody against the vp1 protein of jc virus |
| 01/03/2014 | CA2877584A1 Designed ankyrin repeat proteins binding to platelet-derived growth factor |
| 01/03/2014 | CA2877130A1 Temperature stable vaccine formulations |
| 01/03/2014 | CA2803566A1 Syringe |
| 01/02/2014 | US20140005242 Allantoin-Containing Skin Cream |
| 01/02/2014 | US20140004193 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome |
| 01/02/2014 | US20140004190 Solid Dosage Forms of Bendamustine |
| 01/02/2014 | US20140004185 Pharmaceutical composition |
| 01/02/2014 | US20140004181 Compositions and methods for exosome targeted expression |
| 01/02/2014 | US20140004178 Omv vaccine against burkholderia infections |
| 01/02/2014 | US20140004152 Milk-based protein hydrolysates and infant formulae and nutritional compositions made thereof |
| 01/02/2014 | US20140004151 Antigens and Epitopes Derived From Mycobacterium Tuberculosis |
| 01/02/2014 | US20140004150 Vaccine Injection, Preparation Method and Use Thereof |
| 01/02/2014 | US20140004149 Immunogenic Influenza Composition |
| 01/02/2014 | US20140004148 Methods and Compositions for Inhibiting Diseases of the Central Nervous System |
| 01/02/2014 | US20140004147 Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses |
| 01/02/2014 | US20140004144 Attenuated Streptococcus suis Vaccines and Methods of Making and Use Thereof |
| 01/02/2014 | US20140004143 Adeno-associated virus (aav) serotype 8 sequences, vectors containing same, and uses therefor |
| 01/02/2014 | US20140004140 Group b streptococcus vaccine |
| 01/02/2014 | US20140004135 Yeast-brachyury immunotherapeutic compositions |
| 01/02/2014 | US20140004131 Antibody formulation |
| 01/02/2014 | US20140004126 Therapy and method for intratumorally introducing cytotoxic t lymphocyte and/or nkt cell with anti-tnf and/or anti-il-10 |
| 01/02/2014 | US20140004124 Monoclonal antibodies for cspg4 for the diagnosis and treatment of basal breast carcinoma |
| 01/02/2014 | US20140004123 Monoclonal antibody production by ebv transformation of b cells |
| 01/02/2014 | US20140004122 Methods for treating or preventing cholesterol related disorders |
| 01/02/2014 | US20140004120 Novel anti-dr5 antibody |
| 01/02/2014 | US20140004119 Agonistic antibodies to trkc receptors and uses thereof |
| 01/02/2014 | US20140004118 Clostridium difficile antibodies |
| 01/02/2014 | US20140004116 Methods of preventing or treating pain using anti-ngf antibodies |
| 01/02/2014 | US20140004115 Methods of preventing or treating pain using anti-ngf antibodies that selectively inhibit the association of ngf with trka, without affecting the association of ngf with p75 |
| 01/02/2014 | US20140004113 Defensin-antigen fusion proteins |
| 01/02/2014 | US20140004112 Therapeutic Peptides |
| 01/02/2014 | US20140004111 Polycyclic agents for the treatment of respiratory syncytial virus infections |
| 01/02/2014 | US20140004110 Anti cd37 antibodies |
| 01/02/2014 | US20140004106 Stable igg4 based binding agent formulations |
| 01/02/2014 | US20140004104 Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent |
| 01/02/2014 | US20140004103 Method of treating malignant mesothelioma |
| 01/02/2014 | US20140004095 Albumin fusion proteins |
| 01/02/2014 | US20140004081 Re-Directed Immunotherapy |
| 01/02/2014 | US20140004079 In vivo dendritic cell therapeutic adjuvant |
| 01/02/2014 | US20140004038 Combinatorial therapy |
| 01/02/2014 | US20140004037 Stabilization of the anti-cd20 antibody rituximab |
| 01/01/2014 | EP2679683A2 Novel varicella-zoster virus strains, and chicken pox and herpes zoster virus vaccine using same |
| 01/01/2014 | EP2679681A1 Fc riib-specific fc antibody |
| 01/01/2014 | EP2679677A1 Composition for use in Mycobacteria therapy |
| 01/01/2014 | EP2679600A1 Anti-FGFR3 antibodies and methods using same |
| 01/01/2014 | EP2679599A1 Antibodies directed to Angiopoietin-1 and Angiopoietin-2 and use thereof |
| 01/01/2014 | EP2679596A1 HIV-1 env glycoprotein variant |
| 01/01/2014 | EP2679245A2 Formulations which stabilize and inhibit precipitation of immunogenic compositions |
| 01/01/2014 | EP2679244A2 Formulations which stabilize and inhibit precipitation of immunogenic compositions |
| 01/01/2014 | EP2679242A1 Adjuvant for transdermal or transmucosal administration and pharmaceutical preparation containing same |
| 01/01/2014 | EP2679241A1 Assay for benzylpiperazines and metabolites |
| 01/01/2014 | EP2679240A1 Vaccines including antigen from four strains of influenza virus |
| 01/01/2014 | EP2679232A1 Composition for use in Mycobacteria vaccination |
| 01/01/2014 | EP2679225A1 Pharmaceutical compound with synergistic effect of direct catalase inhibitors and modulators for NO metabolism which lead to catalase destruction or extracellular superoxide anion production |
| 01/01/2014 | EP2678433A1 Delivery of proteins using adeno-associated virus (aav) vectors |
| 01/01/2014 | EP2678361A2 Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use |
| 01/01/2014 | EP2678359A2 Combination therapies comprising anti-erbb3 agents |
| 01/01/2014 | EP2678358A1 Antibodies against human il33r and uses thereof |
| 01/01/2014 | EP2678356A1 Method for treating liver inflammation, fibrosis and non-alcoholic steatohepatitis. |
| 01/01/2014 | EP2678351A1 Rapid selection method for hiv gp-120 variants |
| 01/01/2014 | EP2678034A2 Anti-endoglin antibodies and knockin mice expressing novel human/mouse chimeric endoglin |
| 01/01/2014 | EP2678033A2 Treatment and prevention of malaria |
| 01/01/2014 | EP2678032A1 Lentiviral vectors containing an mhc class i promoter |
| 01/01/2014 | EP2678031A2 Combined cell based gp96-ig-siv/hiv, recombinant gp120 protein vaccination for protection from siv/hiv |
| 01/01/2014 | EP2678030A2 Production of n- and o-sialylated tnfrii-fc fusion protein in yeast |